ASH 2021: Key Data in Chronic Myeloid Leukemia
Shared insight on updates in the chronic myeloid leukemia treatment landscape following the ASH 2021 annual meeting.
Data from the following clinical trials are discussed:
- 310: Efficacy and safety results from ASCEMBL, a multicenter, open-label, phase 3 study of asciminib, a first-in-class STAMP inhibitor, vs bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 tyrosine kinase inhibitors: update after 48 weeks
- 307: Post hoc analysis of responses to ponatinib in patients with chronic-phase chronic myeloid leukemia (CP-CML) by baseline BCR-ABL1 level and baseline mutation status in the Optic trial
Supported in part by Takeda Oncology. Content developed independently by Onclive®.
Related Videos
Related Content
